新里程：三季度末以来各经营主体的业绩开始大幅企稳回升

Core Insights - The company reported that its performance reached a low point in Q3 due to challenges from healthcare policy adjustments and pharmaceutical procurement [2] - Since the end of Q3, the company has implemented various measures leading to a significant recovery and growth in performance [2] Medical Sector - The medical segment has effectively responded to healthcare payment challenges through proactive discipline construction and cost structure optimization [2] - New hospital construction and the development of non-medical insurance-dependent disciplines have enhanced regional competitiveness and service capabilities [2] - Overall, the market share and profits of medical institutions have steadily increased [2] Pharmaceutical Sector - The pharmaceutical segment, led by "Duyiwei Pharmaceutical," has seen fundamental improvements in performance since September through comprehensive optimization of sales, products, and markets [2] - The introduction of strategic investors is driving Duyiwei's transition into a national pharmaceutical group [2] Future Outlook - The company plans to deepen its "health technology" positioning through continuous asset injections [2] - There is a focus on exploring innovative business segments that represent new productive forces to build new growth engines for the future [2]